Notwithstanding encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from pharmacy benefit managers. The https://dianeqoff008178.win-blog.com/23344261/company-s-medication-faces-is-meeting-pbm-hurdles-a-look-of-access-battles